Vermutlich die günstigste und bisher unendeckte Alzheimer/Parkinson Aktie die es gibt ..


Marktkap €10 M-- Cash €11,2 M -- Aktienanzahl 3,6 M--Float 1,2 M --Alzheimer Phase 1b daten diesen Quartal und die Parkinson Phase 2 Daten gibts nächsten Quartal . Bei positiven Daten könnte diese extreme low float Aktie wie eine Rakete davon fliegen . Viel Glück



Theranexus (ALTHX.PA)
Marktkap: €10 M
Cash: €11,2 M
Kurs: €2,81

Aktienanzahl: 3,62 M



Produkt Pipeline
https://www.theranexus.com/images/co...d-pipeline.png


Präsentation
https://www.theranexus.com/images/pd...ion_062019.pdf


Euronext kurs daten
https://live.euronext.com/fr/product...013286259-ALXP


Halbjahresdaten
https://www.theranexus.com/images/pd...lts_vFINAL.pdf


Drug Candidate THN201 –Completion of recruitment for the Phase Ib trial to treat Alzheimer's disease-related neurocognitive disorders

On 17 September, Theranexus announced inclusion of the last healthy subject in its Phase Ib trial comparing the pharmacological efficacy of its drug candidate THN201 with the standard-of-care treatment in Alzheimer's disease-related neurocognitive disorders.The results are expected in Q4 2019


Drug Candidate THN102 –Parkinson's Disease and Narcolepsy

On 24 September, Theranexus announced the recruitment of its last patient with Parkinson's disease naive of any treatment for this pathology to its Phase II clinical trial which aims to evaluate the tolerance and efficacy of its drug candidate THN102 (modafinil/flecainide combination) on non-motor symptoms of the disease (drowsiness, attention and cognitive disorders).This triad, a major unmet medical need in the disease, has a very high market value potential (estimated at over $2 billion). The results for THN102 are expected in Q1 2020.



Größten Aktionäre

Auriga Partners ...14,50 %
Supernova Invest ...13,90 %
Mathieu Charveriat ...10,20 %
Franck Mouthon ...10,20 %
Sofimac Régions ...9,80 %
Kreaxi ...5,10 %
Richard Platford ...3,30 %



Größten Aktionäre Auriga Partners ...14,50 % Supernova Invest ...13,90 % Mathieu Charveriat ...10,20 % Franck Mouthon ...10,20 % Sofimac Régions ...9,80 % Kreaxi ...5,10 % Richard Platford ...3,30 %

ALTHX.PA (Mkap € 8,6 M) Alzheimer & Parkinson Daten in 4Q und 1Q | wallstreet-online.de - Vollständige Diskussion unter:
https://www.wallstreet-online.de/dis...on-daten-4q-1q